Literature DB >> 24267419

Aesthetic uses of the botulinum toxin.

Andrew Dorizas1, Nils Krueger, Neil S Sadick.   

Abstract

The cosmetic use of botulinum toxin (BoNT) is the most common cosmetic procedure performed in the world today. Common adverse events seen in the aesthetic use of the BoNT include swelling, localized bruising, headaches, injection site discomfort, excessive muscle weakness, and unintended paresis of adjacent muscles. BoNT has a wide array of cosmetic uses, including treatment of glabellar lines, chemical browlift, forehead wrinkles, periorbital, and perioral lines. The future formulations and applications of BoNT type A will be plentiful, and are exciting to consider.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  BoNTA; Botulinum neurotoxin; Facial rhytides; Fillers; Glabellar lines; Perioral rhytides

Mesh:

Substances:

Year:  2014        PMID: 24267419     DOI: 10.1016/j.det.2013.09.009

Source DB:  PubMed          Journal:  Dermatol Clin        ISSN: 0733-8635            Impact factor:   3.478


  11 in total

1.  New approach for the rational selection of markers to identify botulinum toxins.

Authors:  Osnat Rosen; Liron Feldberg; Eyal Dor; Ran Zichel
Journal:  Arch Toxicol       Date:  2021-02-10       Impact factor: 5.153

2.  EUS-Guided Intragastric Injection of Botulinum Toxin A in the Preoperative Treatment of Super-Obese Patients: a Randomized Clinical Trial.

Authors:  Eduardo Guimarães Hourneaux de Moura; Igor Braga Ribeiro; Mariana Souza Varela Frazão; Luiz Henrique Mazzonetto Mestieri; Diogo Turiani Hourneaux de Moura; Creusa Maria Roveri Dal Bó; Vitor Ottoboni Brunaldi; Eduardo Turiani Hourneaux de Moura; Gabriel Cairo Nunes; Fábio Alberto Castillo Bustamante; Manoel Dos Passos Galvão Neto; Sergio Eiji Matuguma; Wanderley Marques Bernardo; Marco Aurélio Santo
Journal:  Obes Surg       Date:  2019-01       Impact factor: 4.129

3.  Emerging Trends in Botulinum Neurotoxin A Resistance: An International Multidisciplinary Review and Consensus.

Authors:  Wilson W S Ho; Philipp Albrecht; Pacifico E Calderon; Niamh Corduff; David Loh; Michael U Martin; Je-Young Park; Lis S Suseno; Fang-Wen Tseng; Vasanop Vachiramon; Rungsima Wanitphakdeedecha; Chong-Hyun Won; Jonathan N T Yu; Mary Dingley
Journal:  Plast Reconstr Surg Glob Open       Date:  2022-06-20

4.  Global Trends of Botulinum Toxin Literature: A Bibliometric Analysis of Botulinum Toxin Publications Between 1975 and 2017.

Authors:  Engin Şenel; Ümran Muslu
Journal:  J Cutan Aesthet Surg       Date:  2020 Apr-Jun

Review 5.  AbobotulinumtoxinA: A 25-Year History.

Authors:  Gary D Monheit; Andy Pickett
Journal:  Aesthet Surg J       Date:  2017-05-01       Impact factor: 4.283

6.  Neuronal entry and high neurotoxicity of botulinum neurotoxin A require its N-terminal binding sub-domain.

Authors:  Jiafu Wang; Jianghui Meng; Marc Nugent; Minhong Tang; J Oliver Dolly
Journal:  Sci Rep       Date:  2017-03-15       Impact factor: 4.379

7.  Functional detection of botulinum neurotoxin serotypes A to F by monoclonal neoepitope-specific antibodies and suspension array technology.

Authors:  Laura von Berg; Daniel Stern; Diana Pauly; Stefan Mahrhold; Jasmin Weisemann; Lisa Jentsch; Eva-Maria Hansbauer; Christian Müller; Marc A Avondet; Andreas Rummel; Martin B Dorner; Brigitte G Dorner
Journal:  Sci Rep       Date:  2019-04-02       Impact factor: 4.379

8.  Efficacy and Safety of PrabotulinumtoxinA for the Treatment of Glabellar Lines in Adult Subjects: Results From 2 Identical Phase III Studies.

Authors:  Kenneth R Beer; Ava Theresa Shamban; Rui L Avelar; John E Gross; Anneke Jonker
Journal:  Dermatol Surg       Date:  2019-11       Impact factor: 3.398

Review 9.  Botulinum Toxin in Aesthetic Medicine: Myths and Realities.

Authors:  Jeffrey S Dover; Gary Monheit; Mark Greener; Andy Pickett
Journal:  Dermatol Surg       Date:  2018-02       Impact factor: 3.398

10.  Repeated OnabotulinumtoxinA Treatment of Glabellar Lines at Rest Over Three Treatment Cycles.

Authors:  Alastair Carruthers; Jean Carruthers; Steven Fagien; Xiaofang Lei; Julia Kolodziejczyk; Mitchell F Brin
Journal:  Dermatol Surg       Date:  2016-09       Impact factor: 3.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.